Get the Stockscreener App
9.96
2.10%
0.205
Rapport Therapeutics Inc stock is traded at $9.96, with a volume of 163.47K.
It is up +2.10% in the last 24 hours and up +2.05% over the past month.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
See More
Previous Close:
$9.755
Open:
$9.76
24h Volume:
163.47K
Relative Volume:
0.78
Market Cap:
$363.54M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-2.83%
1M Performance:
+2.05%
6M Performance:
-52.46%
1Y Performance:
+0.00%
1-Day Range:
$9.76
$10.29
1-Week Range:
$9.20
$10.83
52-Week Range:
$7.13
$29.74
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Name
Rapport Therapeutics Inc
Sector
Industry
Phone
857-321-8020
Address
1325 BOYLSTON STREET, BOSTON
Compare RAPP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
9.96 | 374.10M | 0 | 0 | 0 | 0.00 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-02-24 | Initiated | Jefferies | Buy |
| Jul-02-24 | Initiated | Stifel | Buy |
| Jul-02-24 | Initiated | TD Cowen | Buy |
Rapport Therapeutics Inc Stock (RAPP) Latest News
Companies Like Rapport Therapeutics (NASDAQ:RAPP) Are In A Position To Invest In Growth - Yahoo Finance
Rapport Therapeutics Reports Q1 2025 Financial Results - MSN
Wells Fargo & Company MN Grows Stake in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Barclays PLC Buys 5,634 Shares of Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Rapport Therapeutics, Inc. SEC 10-Q Report - TradingView
Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update - The Manila Times
(RAPP) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Rapport Therapeutics (NASDAQ:RAPP) Shares Acquired by JPMorgan Chase & Co. - Defense World
Legal & General Group Plc Buys 8,614 Shares of Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Shares Acquired by Geode Capital Management LLC - Defense World
Rapport Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
When the Price of (RAPP) Talks, People Listen - news.stocktradersdaily.com
Rapport therapeutics chief scientific officer sells $81,310 of stock - Investing.com Australia
Rapport therapeutics chief scientific officer sells $81,310 of stock By Investing.com - Investing.com South Africa
KLP Kapitalforvaltning AS Purchases Shares of 1,900 Rapport Therapeutics (NASDAQ:RAPP) - Defense World
48,452 Shares in Rapport Therapeutics (NASDAQ:RAPP) Acquired by Norges Bank - Defense World
Comparing Rapport Therapeutics (RAPP) & The Competition - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Coverage Initiated at JMP Securities - Defense World
JMP Securities Initiates Coverage of Rapport Therapeutics (RAPP) with Market Outperform Recommendation - Nasdaq
Citizens JMP sets $28 target for Rapport Therapeutics stock By Investing.com - Investing.com Canada
(RAPP) Investment Analysis - news.stocktradersdaily.com
nCino Posts Weak Earnings, Joins Tesla And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Rapport Therapeutics: Too Early To Be Interesting (NASDAQ:RAPP) - Seeking Alpha
Swiss National Bank Purchases New Stake in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Analyzing Neurogene (NASDAQ:NGNE) & Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
(RAPP) Long Term Investment Analysis - news.stocktradersdaily.com
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Benzinga
Validea Kenneth Fisher Strategy Daily Upgrade Report3/25/2025 - Nasdaq
Vanda Pharmaceuticals (NASDAQ:VNDA) and Rapport Therapeutics (NASDAQ:RAPP) Financial Contrast - Defense World
Rapport Therapeutics to present data at 2025 AAN meeting - TipRanks
Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting - GlobeNewswire
Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting - GlobeNewswire Inc.
Several Insiders Invested In Rapport Therapeutics Flagging Positive News - simplywall.st
Positive Signs As Multiple Insiders Buy Rapport Therapeutics Stock - Yahoo
Insider Buying: Rapport Therapeutics Chief Financial Officer Bought US$101k Of Shares - Yahoo Finance
Rapport Therapeutics director Wendy Young acquires $61,249 in stock By Investing.com - Investing.com India
Rapport Therapeutics CFO Troy Ignelzi buys $100,988 in stock - Investing.com
Rapport Therapeutics CFO Troy Ignelzi buys $100,988 in stock By Investing.com - Investing.com India
Rapport Therapeutics Executives Acquire Shares - TradingView
Rapport Therapeutics director Wendy Young acquires $61,249 in stock - Investing.com
Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Rapport Therapeutics Reports Q4 Net Loss Of $19.98 Mln - Nasdaq
Rapport Therapeutics, Inc. SEC 10-K Report - TradingView
Rapport Therapeutics reports Q4 EPS (57c) vs. ($8.01) last year - TipRanks
Rapport Therapeutics Inc Q4 Net Loss $20.0 Million -March 11, 2025 at 07:20 am EDT - Marketscreener.com
Rhumbline Advisers Has $182,000 Stock Position in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
New York State Common Retirement Fund Acquires New Position in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
(RAPP) On The My Stocks Page - Stock Traders Daily
Head of R&D Robert Lenz to leave Neumora - BioCentury
Rapport Therapeutics appoints new chief medical officer By Investing.com - Investing.com Canada
Rapport Therapeutics Inc Stock (RAPP) Financials Data
There is no financial data for Rapport Therapeutics Inc (RAPP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Rapport Therapeutics Inc Stock (RAPP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bredt David | Chief Scientific Officer |
Mar 14 '25 |
Sale |
10.85 |
8,500 |
92,205 |
469,142 |
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):